277 reports of this reaction
1.5% of all AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE reports
#20 most reported adverse reaction
OEDEMA PERIPHERAL is the #20 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 277 FDA adverse event reports linking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE to OEDEMA PERIPHERAL. This represents approximately 1.5% of all 18,930 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE who experience oedema peripheral should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OEDEMA PERIPHERAL is a less commonly reported adverse event for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to oedema peripheral, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE:
The following drugs have also been linked to oedema peripheral in FDA adverse event reports:
OEDEMA PERIPHERAL has been reported as an adverse event in 277 FDA reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OEDEMA PERIPHERAL accounts for approximately 1.5% of all adverse event reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, making it a notable side effect.
If you experience oedema peripheral while taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.